{"url_path":"/sec/mplt/8-k/2026-06-24/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1770069/0001193125-26-280243-index.html","accession_number":"0001193125-26-280243","cik":"0001770069","ticker":"MPLT","issuer_name":"MapLight Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1770069/0001193125-26-280243-index.html","primary_entity_key":"0001770069","primary_entity_name":"MapLight Therapeutics, Inc."},"word_count":267,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Security Holders.\n\nOn June 23, 2026, MapLight Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2026 (the “Proxy Statement”). Of the 42,610,079 shares outstanding as of the record date, 36,883,750 shares, or approximately 86.56%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.\n\nProposal No. 1: Election of three nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:\n\n \n\nName\n\n  \nVotes For\n \n  \nVotes Withheld\n \n\nMartin Babler\n\n  \n \n31,424,194\n \n  \n \n3,575,737\n \n\nTroy Cox\n\n  \n \n34,979,012\n \n  \n \n20,919\n \n\nGeorge Pavlov\n\n  \n \n34,220,342\n \n  \n \n779,589\n \n\nBroker Non-Votes: 1,883,819\n\nAll nominees were elected.\n\nProposal No. 2: Ratification of the selection of RSM US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows:\n\n \n\n \n  \nVotes For\n \n  \nVotes Against\n \n  \nAbstained\n \n\nRatification of selection of RSM US LLP\n\n  \n \n36,859,217\n \n  \n \n22,332\n \n  \n \n2,201\n \n\nBroker Non-Votes: 0\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nMapLight Therapeutics, Inc.\n\nDated: June 24, 2026\n \n\n \nBy:\n \n\n/s/ Christopher A. Kroeger\n\n \n\n \n\n \nChristopher A. Kroeger, M.D.\n\n \n\n \n\n \nChief Executive Officer"}